SCHEMBL4374841

SCHEMBL4374841

Nc1ccc(Oc2ccc(F)cc2F)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 1/20 0.58
MAPK14 Q16539 2/20 0.49
ALDH1A1 P00352 4/20 0.48
CYP3A4 P08684 1/20 0.48
TSHR P16473 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
SCN4A P35499 1/20 0.48
AR P10275 1/20 0.48
NCOA1 Q15788 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MITF O75030 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
GFER P55789 1/20 0.44
NLRP1 Q9C000 1/20 0.44
NOD2 Q9HC29 1/20 0.44
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3024118 0.89 HSPB1 (0.50) HSPB1MAPK14ALDH1A1CYP3A4TSHR
SCHEMBL31287801 0.89 HSPB1 (0.50) HSPB1MAPK14ALDH1A1CYP3A4TSHR
SCHEMBL21104547 0.88 ALDH1A1 (0.52) HSPB1MAPK14ALDH1A1CYP3A4TSHR
SCHEMBL13857904 0.85 ALDH1A1 (0.48) HSPB1ALDH1A1CYP3A4TSHRTDP1
SCHEMBL10561428 0.81 MAPT (0.57) HSPB1ALDH1A1CYP3A4TSHRTDP1
SCHEMBL1371520 0.81 ALDH1A1 (0.48) HSPB1ALDH1A1CYP3A4TSHRTDP1
SCHEMBL14965170 0.81 MAOA (0.57) ALDH1A1CYP3A4TSHRTDP1MEN1
SCHEMBL21186209 0.81 PDE7A (0.56) ALDH1A1CYP3A4TSHRTDP1NCOA1
SCHEMBL31264488 0.81 PDE7A (0.56) ALDH1A1CYP3A4TSHRTDP1NCOA1
SCHEMBL4372913 0.81 HSPB1 (0.58) HSPB1MAPK14SCN4AARTRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084056-A1 SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-03-13 US disclosed
US-20220213092-A1 BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS ABBVIE INC (US) 2022-07-07 US disclosed
WO-2022132997-A1 BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS ABBVIE INC. (US) 2022-06-23 WO disclosed
US-20200247808-A1 Heterocyclic Tec-Family Kinase Inhibitors GB005, INC. 2020-08-06 US disclosed
WO-2019141980-A1 AGRICULTURAL CHEMICALS GLOBACHEM NV (BE) 2019-07-25 WO disclosed
WO-2017041180-A1 HETEROCYCLIC TEC-FAMILY KINASE INHIBITORS PHARMASCIENCE INC. (CA) 2017-03-16 WO disclosed
US-7625932-B2 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-12-01 US disclosed
US-7625932-B2 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-12-01 US disclosed
US-7625932-B2 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-12-01 US disclosed
EP-1670757-B1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2009-05-06 EP disclosed
EP-1670757-B1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2009-05-06 EP disclosed
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY 2007-03-22 US disclosed
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY 2007-03-22 US disclosed
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY 2007-03-22 US disclosed
WO-2005040110-A1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2005-05-06 WO disclosed
US-6800651-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-10-05 US disclosed
US-20040006114-A1 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-01-08 US disclosed
EP-1255735-A2 PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2002-11-13 EP disclosed
WO-2001056990-A2 PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247808-A1 Heterocyclic Tec-Family Kinase Inhibitors TEC, BTK, LCK HSPB1 2608/4885MAPK14 262/4885ALDH1A1 4469/4885
US-20250084056-A1 SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS CCNA1, CCNI, CCNE1 HSPB1 2029/4885MAPK14 2446/4885ALDH1A1 431/4885
US-20220213092-A1 BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS BTK, LYN, ABL1 HSPB1 4429/4885MAPK14 869/4885ALDH1A1 3541/4885
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors GRIN1, GRIN3A, GRIK5 HSPB1 4378/4885MAPK14 1837/4885ALDH1A1 2211/4885
US-20040006114-A1 Potentiators of glutamate receptors GRM1, GRIN1, GRM2 HSPB1 3201/4885MAPK14 3282/4885ALDH1A1 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.